Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Isoquercitrin,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
The Effect of Isoquercetin on Thromboembolic Events in Patients with Metastatic Pancreatic Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 06, 2025
Lead Product(s) : Isoquercitrin,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zafirlukast,Inapplicable
Therapeutic Area : Hematology
Study Phase : Phase II
Recipient : Western New England University
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Western New England University and Quercis Pharma Sign Exclusive Worldwide License Agreements
Details : Zafirlukast (Accolate®) is in a class of medications known as leukotriene receptor antagonists (LTRAs) that work by blocking the action of certain natural substances that cause swelling and tightening of the airways.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 19, 2021
Lead Product(s) : Zafirlukast,Inapplicable
Therapeutic Area : Hematology
Highest Development Status : Phase II
Recipient : Western New England University
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Isoquercitrin,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : FDA
Deal Size : Undisclosed
Deal Type : Agreement
Quercis Announces Special Protocol Assessment Agreement with U.S. Food and Drug Administration
Details : SPA supports protocol for Phase 3 Trial of Isoquercetin to effect thromboembolic events in metastatic pancreatic cancer patients. Isoquercetin employs a novel pathway that is based on a new mechanism of action to prevent or reverse thrombus formation.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 05, 2021
Lead Product(s) : Isoquercitrin,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : FDA
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Isoquercitrin,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II/ Phase III
Recipient : Beth Israel Deaconess Medical Center
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The patents cover the inhibition of soluble P-selectin that helps to prevent and/or reduce thrombotic events. Quercis’ lead drug candidate ISQ950AN, acts as an antithrombotic with significantly lower risk of adverse events than existing therapies.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 21, 2021
Lead Product(s) : Isoquercitrin,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Recipient : Beth Israel Deaconess Medical Center
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Isoquercitrin,Inapplicable
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Recipient : National Heart, Lung, and Blood Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 17, 2020
Lead Product(s) : Isoquercitrin,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Recipient : National Heart, Lung, and Blood Institute
Deal Size : Inapplicable
Deal Type : Inapplicable